M. Goldstein

Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting

Controlling aberrant RAS signaling has been the subject of intensive efforts aimed at developing specific RAS inhibitors, small molecules that promote RAS degradation, and monobodies that inhibit RAS activity. Direct proteolytic degradation of RAS by site-specific proteases has received considerably less attention. A n...